Greenwich LifeSciences (GLSI) Research & Development (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Research & Development data on file, last reported at $8.3 million in Q4 2025.

• Quarterly Research & Development fell 4.84% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.2 million (up 11.24% YoY) and the FY2025 annual result came in at $17.2 million, up 11.24% from the prior year.
• Research & Development rose to $8.3 million in Q4 2025, from $3.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $8.7 million in Q4 2024 to a low of $281977.0 in Q1 2021.
• A 5-year average of $2.5 million and a median of $2.2 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 488.99% — and 2023, when it fell 5.09%.
• Tracing GLSI's Research & Development over 5 years: stood at $2.1 million in 2021, then advanced by 19.1% to $2.5 million in 2022, then retreated by 5.09% to $2.3 million in 2023, then jumped by 272.3% to $8.7 million in 2024, then declined by 4.84% to $8.3 million in 2025.
• The last three Research & Development figures came in at $8.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.4 million (Q2 2025), per Business Quant data.